Bionano Genomics, Inc. (NASDAQ: BNGO)

$1.24 ▲ +0.00 (+0.40%)
As of May 22, 2026 04:00 PM
Sector: Healthcare Industry: Medical Instruments & Supplies CIK: 0001411690
Market Cap 14.92 Mn
P/E -0.28
P/S 0.52
Div. Yield 0.00
ROIC (Qtr) -0.01
Revenue Growth (1y) (Qtr) 3.56
Add ratio to table...

About

Bionano Genomics, Inc. provides genome analysis solutions that enable researchers and clinicians to answer complex questions in biology and medicine. The company's core offerings include optical genome mapping systems nucleic acid extraction and purification systems diagnostic testing services and software for genomic data analysis. The company generates revenue primarily from the sale of its optical genome mapping instruments such as the Saphyr and Stratys systems. Revenue also comes from the sale of consumables reagents and sample preparation...

Read more

Investment thesis

Bull case

  • Bionano’s pivot from expanding its installed base to deepening utilization among its existing routine users is a strategic masterstroke that unlocks a high‑margin revenue stream. The company already demonstrated that existing customers can lift their sample throughput from an average of four to potentially twenty per week, a lift that would double consumable and software sales without significant incremental capital investment. Coupled with a 46% non‑GAAP gross margin—an impressive swing from 26% last year—this utilization model indicates a sustainable profit engine that can be replicated across its current 384‑unit base. As the organization continues to drive software adoption and menu expansion, the marginal cost of serving each additional sample is negligible, making the growth trajectory almost limitless once the adoption curve stabilizes.
  • The recent CMS determination of a second Category I CPT code for optical genome mapping at a reimbursement level of $1,263.53 materially improves the economic rationale for clinical laboratories to transition from legacy microarray or karyotyping methods. This code not only validates the clinical utility of OGM but also sets a precedent for future codes that could capture even more value. A higher reimbursement ceiling is likely to accelerate routine usage, especially in oncology and constitutional genetics where OGM can provide actionable structural variant insights. The company’s early involvement in the CMS crosswalk and its demonstrated alignment with payer pricing models positions it to capture a sizeable share of this newly monetized service.
  • The expansion of Bionano’s VIA software integration into multi‑modal workflows—encompassing OGM, microarray, and next‑generation sequencing—creates a differentiated data platform that enhances user stickiness. By streamlining analysis across platforms, the company reduces the learning curve and data silos that traditionally hinder adoption of new technologies. The anticipated full commercial release of the upgraded VIA platform will further embed Bionano into routine laboratory pipelines, potentially unlocking additional revenue from license fees and cloud compute services.
  • Scientific momentum is accelerating, as evidenced by 97 new publications in 2025 and a cumulative 11,500 clinical research genomes. These publications reinforce the clinical relevance of OGM and serve as an evidence base that can be leveraged for guideline inclusion by professional societies. The high-profile MD Anderson study benchmarking OGM against RNA‑seq in acute leukemias expands OGM’s appeal beyond cytogenetics into molecular oncology, opening new therapeutic decision‑support avenues. Academic validation often translates into broader clinical acceptance, and Bionano is well positioned to convert this scholarly traction into market share.
  • Japan presents a unique growth catalyst that the company has only lightly surfaced. With a single service‑provider laboratory currently installed, the country offers a near‑unexploited platform for high‑throughput, high‑value research and commercial diagnostics. The presence of pharmaceutical interest in cell‑ and gene‑therapy development signals potential rapid uptake, especially given Japan’s strong regulatory appetite for innovative therapies. If Bionano can secure additional Japanese installations, it would serve as a bellwether for broader Asian expansion, reinforcing its global growth narrative.
Read more

Bear case

  • The reliance on routine users as the primary growth engine introduces a critical risk: the assumption that current laboratories will continue to increase throughput at the projected rates may be overly optimistic. In Q&A, management acknowledged that the “average utilization” sits between four and forty samples per week, yet did not provide a concrete timeline for reaching a high‑utilization plateau. Without a proven conversion framework, many routine users may remain constrained by external factors such as reimbursement limits, sample volume fluctuations, or competing diagnostics, potentially stalling the expected revenue lift.
  • While the CMS CPT code is a positive signal, it remains a preliminary determination pending final payment policy implementation. The proposed reimbursement of $1,263.53, though higher than microarray codes, still falls short of the true economic value derived from OGM in complex cases, and payers may impose additional utilization caps or prior‑authorization requirements. A conservative reimbursement rollout could dampen the expected increase in routine usage, especially in oncology where cost‑effectiveness analyses are increasingly stringent.
  • The installed base expansion has been minimal, with only 23 new systems installed in the first nine months of 2025 and a net increase of three systems in the quarter. This sluggish growth suggests that market penetration remains limited, and Bionano’s sales and marketing spend may not be translating into tangible adoption. If the pipeline of new installations stalls, the company will face the risk of cannibalizing revenue from existing customers rather than capturing new ones, which would constrain top‑line growth.
  • The company’s heavy dependence on consumables and software as revenue drivers could become a double‑edged sword. While these segments offer higher margins, they are also sensitive to macro‑economic cycles that affect laboratory budgets. During periods of fiscal tightening or reimbursement pressure, labs may cut back on repeat consumable purchases, slowing revenue even if the installed base remains unchanged. Additionally, the competitive landscape includes other high‑throughput sequencing and microarray vendors that could erode Bionano’s market share in both consumable and software markets.
  • Management’s commitment to keeping operating expenses flat is prudent, yet it also signals limited flexibility to scale sales or invest in critical product areas if the company’s growth assumptions prove inaccurate. Should utilization plateau or new installations lag, the company may find it difficult to justify additional spending on R&D or go‑to‑market initiatives without diluting equity or depleting cash reserves. A rigid expense model could hinder responsiveness to evolving competitive pressures.
Read more

Product and Service Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Instruments & Supplies
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ISRG Intuitive Surgical Inc 156.17 Bn 52.64 14.76 -
2 BDX Becton Dickinson & Co 41.51 Bn 29.74 1.94 17.28 Bn
3 RMD Resmed Inc 30.43 Bn 20.13 5.50 0.26 Bn
4 WST West Pharmaceutical Services Inc 22.78 Bn 42.07 7.07 0.20 Bn
5 SOLV Solventum Corp 13.39 Bn 9.37 1.62 5.08 Bn
6 COO Cooper Companies, Inc. 12.33 Bn 31.01 2.97 2.50 Bn
7 ALGN Align Technology Inc 11.65 Bn 27.31 2.84 -
8 BAX Baxter International Inc 9.81 Bn -72.70 0.91 9.46 Bn